Intelligence Feed event · Equity · 2026-09-03

    Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million

    Question

    Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million

    Direct answer

    Contract research organization Fortrea has executed a binding definitive agreement to purchase the Early Phase Services unit from Worldwide Clinical Trials for a headline purchase price of approximately $45 million. The deal expands Fortrea's laboratory testing and Phase 1 trial execution capabilities. The asset package includes a Good Laboratory Practice (GLP) bioanalytical laboratory located in Austin, Texas, a dedicated 200-bed clinical pharmacology unit situated in San Antonio, Texas, and cold-chain biospecimen repository operations based in Pflugerville, Texas.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/fortrea-acquires-worldwide-clinical-trials-early-phase-unit-for-45-million-679203

    EQUITY
    Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million
    Contract research organization Fortrea has executed a binding definitive agreement to purchase the Early Phase Services unit from Worldwide Clinical Trials for a headline purchase price of approximately $45 million. The deal expands Fortrea's laboratory testing and Phase 1 trial execution capabilities. The asset package includes a Good Laboratory Practice (GLP) bioanalytical laboratory located in Austin, Texas, a dedicated 200-bed clinical pharmacology unit situated in San Antonio, Texas, and cold-chain biospecimen repository operations based in Pflugerville, Texas.
    FTRE
    Impact
    61
    SEP 3
    SIG
    88%
    FTRE
    Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million
    Contract research organization Fortrea has executed a binding definitive agreement to purchase the Early Phase Services unit from Worldwide Clinical Trials for a headline purchase price of approximately $45 million. The deal expands Fortrea's laboratory testing and Phase 1 trial execution capabilities. The asset package includes a Good Laboratory Practice (GLP) bioanalytical laboratory located in Austin, Texas, a dedicated 200-bed clinical pharmacology unit situated in San Antonio, Texas, and cold-chain biospecimen repository operations based in Pflugerville, Texas.
    → Acquiring early-stage clinical pharmacology infrastructure expands Fortrea's capacity for Phase 1 clinical trial contracts and bioanalytical testing fees.
    Impact
    Contract research organization Fortrea has executed a binding definitive agreement to purchase the Early Phase Services unit from Worldwide Clinical Trials for a headline purchase price of approximately $45 million. The deal expands Fortrea's laboratory testing and Phase 1 trial execution capabilities. The asset package includes a Good Laboratory Practice (GLP) bioanalytical laboratory located in Austin, Texas, a dedicated 200-bed clinical pharmacology unit situated in San Antonio, Texas, and cold-chain biospecimen repository operations based in Pflugerville, Texas.
    Affected
    FTRE
    Transmission
    Acquiring early-stage clinical pharmacology infrastructure expands Fortrea's capacity for Phase 1 clinical trial contracts and bioanalytical testing fees.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    FTRErevenue expansion via contract research capacity additionUp1-4wFortrea signs binding $45 million acquisition agreement for early-phase clinical operations

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month